HROW - Harrow Health, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.41
+0.26 (+5.05%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close5.15
Open5.19
Bid4.82 x 1300
Ask5.67 x 1200
Day's Range5.11 - 5.47
52 Week Range3.33 - 8.99
Volume73,427
Avg. Volume175,363
Market Cap138.598M
Beta (5Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.94
Earnings DateAug 12, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
  • These Analysts Just Made A Massive Downgrade To Their Harrow Health, Inc. (NASDAQ:HROW) EPS Forecasts
    Simply Wall St.

    These Analysts Just Made A Massive Downgrade To Their Harrow Health, Inc. (NASDAQ:HROW) EPS Forecasts

    The latest analyst coverage could presage a bad day for Harrow Health, Inc. (NASDAQ:HROW), with the analysts making...

  • Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates

    Harrow (HROW) delivered earnings and revenue surprises of 0.00% and 16.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Harrow Health Publishes First Quarter 2020 Letter to Stockholders

    While it is difficult to predict what the rest of 2020 will look like, we are starting to see orders come in as our customers re-open and we continue to be excited about Harrow’s upcoming events, catalysts, and developments in the near and long-term. The Company also owns royalty rights in certain drug candidates being developed by Surface, Melt, Mayfield and Radley.

  • Is Harrow Health (NASDAQ:HROW) Weighed On By Its Debt Load?
    Simply Wall St.

    Is Harrow Health (NASDAQ:HROW) Weighed On By Its Debt Load?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

  • GlobeNewswire

    Harrow Health to Announce First Quarter 2020 Financial Results on May 11, 2020

    Harrow Health, Inc. (HROW) today announced that after the close of trading on Monday, May 11, 2020, it will release first quarter 2020 financial results and host a conference call at 5:00 p.m. Eastern Daylight Time / 2:00 p.m. Pacific Daylight Time to discuss the financial results and recent business developments. After the close of the market on May 11, 2020, Harrow will issue a press release containing a link to its first quarter 2020 Letter to Stockholders. On the conference call, the primary objective is to allow analysts to engage in a question and answer session with the Harrow management team after providing a brief introduction, an overview of the quarter, and outlook for the business.

  • GlobeNewswire

    ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine Services

    Harrow Health, Inc. (HROW) and ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow, announced that they have entered into an exclusive agreement with Doxy.me, a full-service telemedicine solution. Doxy.me is one of the largest, yet simplest, telemedicine software solutions in the world, providing video, audio and text through which patients and healthcare providers can seamlessly communicate remotely.

  • GlobeNewswire

    Harrow Health Appoints Teresa Sparks to its Board of Directors

    Harrow Health, Inc. (HROW) today announced the appointment of Teresa Sparks to its Board of Directors. As Harrow continues to drive shareholder value by founding, developing, and deconsolidating companies like Eton, Surface, and Melt, I anticipate Teresa’s impressive experience as a healthcare leader of both private and publicly traded companies will be an invaluable asset.

  • Harrow Health (HROW) Q4 Earnings and Revenues Lag Estimates
    Zacks

    Harrow Health (HROW) Q4 Earnings and Revenues Lag Estimates

    Harrow (HROW) delivered earnings and revenue surprises of -23.08% and -10.16%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Harrow Health Publishes Fourth Quarter 2019 Letter to Stockholders

    The company is not expecting disruptions in its business or supply chain as a result of the recent COVID-19 virus concerns in the US and around the world. The company has double checked inventories and its sources of key active pharmaceutical ingredients and other materials. In addition, the company has been in contact with its insurance provider and believes it has adequate coverage through its various risk management policies that could help supplement any losses in the unlikely event a potentially recoverable claim was to occur.

  • Should You Be Impressed By Harrow Health, Inc.'s (NASDAQ:HROW) ROE?
    Simply Wall St.

    Should You Be Impressed By Harrow Health, Inc.'s (NASDAQ:HROW) ROE?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • GlobeNewswire

    ImprimisRx® Announces Supply Agreement with EyeCare Services Partners

    ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that it has agreed to a product supply agreement with EyeCare Services Partners (ESP). ImprimisRx currently provides a limited number of ophthalmic formulations to practices within the ESP group, but this agreement will expand the number of formulations available to new and existing ESP facilities and allow for additional formulations to be added as the ImprimisRx/ESP relationship continues to expand. ESP is a partnership of 30+ ophthalmologic, optometric brands, and ambulatory surgery centers (ASCs) across multiple states, with 90 locations, 12 ASCs, and 200 providers, representing approximately 100,000 ophthalmic procedures in the U.S. annually.

  • GlobeNewswire

    ImprimisRx® Announces Supply Agreement with iOR Partners

    ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that it has agreed to a product supply agreement with iOR Partners. Under the agreement, ImprimisRx will provide a variety of formulations needed for in-office surgeries, including the MKO Melt® and various injectable and topical products.

  • Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for

    Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA)

    ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that it has agreed to a product supply agreement with Vision Center Network of America, LLC (VCNA). The agreement will make ImprimisRx a VCNA preferred provider for a variety of surgical formulations, including a portfolio of topical and injectable products.

  • GlobeNewswire

    Harrow Health to Announce Fourth Quarter 2019 Financial Results on March 13, 2020

    Harrow Health, Inc. (HROW) today announced that before the open of trading on Friday, March 13, 2020, it will release fourth quarter 2019 financial results and host a conference call at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time to discuss the financial results and recent business developments. Prior to the open of the market on March 13, 2020, at approximately 8:00 a.m. Eastern Daylight Time / 5:00 a.m. Pacific Daylight Time, Harrow will issue a press release containing a link to its fourth quarter 2019 Letter to Stockholders. On the conference call, the primary objective is to allow analysts to engage in a question and answer session with the Harrow management team after providing a brief introduction and overview of the quarter and outlook for the business.

  • Implied Volatility Surging for Harrow Health (HROW) Stock Options
    Zacks

    Implied Volatility Surging for Harrow Health (HROW) Stock Options

    Investors need to pay close attention to Harrow Health (HROW) stock based on the movements in the options market lately.

  • Why Harrow Health, Inc.'s (NASDAQ:HROW) CEO Pay Matters To You
    Simply Wall St.

    Why Harrow Health, Inc.'s (NASDAQ:HROW) CEO Pay Matters To You

    Mark Baum has been the CEO of Harrow Health, Inc. (NASDAQ:HROW) since 2012. This report will, first, examine the CEO...

  • Is Harrow Health, Inc. (HROW) A Good Stock To Buy?
    Insider Monkey

    Is Harrow Health, Inc. (HROW) A Good Stock To Buy?

    Is Harrow Health, Inc. (NASDAQ:HROW) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]

  • The Harrow Health (NASDAQ:HROW) Share Price Is Up 256% And Shareholders Are Boasting About It
    Simply Wall St.

    The Harrow Health (NASDAQ:HROW) Share Price Is Up 256% And Shareholders Are Boasting About It

    It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

  • Inventor Of "LessDrops," Surgical Eyedrop, Wins Return Of Patent From Harrow Health
    PR Newswire

    Inventor Of "LessDrops," Surgical Eyedrop, Wins Return Of Patent From Harrow Health

    Novel Drug Solutions, LLC and Eye Care Northwest, PA, announce the return of their unrestricted patent rights to several awarded and pending USA and international patents previously controlled by Harrow Health, Inc. (NASDAQ: HROW formerly known as Imprimis Pharmaceuticals, Inc.).

  • GlobeNewswire

    ImprimisRx’s FDA-Registered Outsourcing Facility Issued California License

    ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (HROW), announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California. This license allows California-based ophthalmologists, optometrists, surgery centers and hospitals to efficiently order and stock ImprimisRx’s more than 40 ophthalmic products for on-demand administration to their patients.

  • Harrow Health (HROW) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Harrow Health (HROW) Reports Q3 Loss, Misses Revenue Estimates

    Harrow (HROW) delivered earnings and revenue surprises of -2.27% and -4.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Harrow Health Publishes Third Quarter Letter to Stockholders

    NASHVILLE, Tenn., Nov. 13, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2019.  Please click here to review Harrow Health’s.

  • Earnings Preview: Harrow Health (HROW) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: Harrow Health (HROW) Q3 Earnings Expected to Decline

    Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Publicly traded health care company signs lease for Green Hills headquarters
    American City Business Journals

    Publicly traded health care company signs lease for Green Hills headquarters

    The new office will be the first physical footprint the company has made in Music City since it announced it was moving its headquarters from San Diego to Nashville in June.